- Home
- FMY vs MAIA Comparison
FMY vs MAIA Comparison
Compare FMY & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMY
- MAIA
- Stock Information
- Founded
- FMY 2005
- MAIA 2018
- Country
- FMY United States
- MAIA United States
- Employees
- FMY N/A
- MAIA N/A
- Industry
- FMY Finance/Investors Services
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- FMY Finance
- MAIA Health Care
- Exchange
- FMY Nasdaq
- MAIA Nasdaq
- Market Cap
- FMY 49.6M
- MAIA 46.7M
- IPO Year
- FMY N/A
- MAIA 2022
- Fundamental
- Price
- FMY $12.05
- MAIA $1.82
- Analyst Decision
- FMY
- MAIA
- Analyst Count
- FMY 0
- MAIA 0
- Target Price
- FMY N/A
- MAIA N/A
- AVG Volume (30 Days)
- FMY 10.1K
- MAIA 341.6K
- Earning Date
- FMY 01-01-0001
- MAIA 05-09-2025
- Dividend Yield
- FMY 6.98%
- MAIA N/A
- EPS Growth
- FMY N/A
- MAIA N/A
- EPS
- FMY N/A
- MAIA N/A
- Revenue
- FMY N/A
- MAIA N/A
- Revenue This Year
- FMY N/A
- MAIA N/A
- Revenue Next Year
- FMY N/A
- MAIA N/A
- P/E Ratio
- FMY N/A
- MAIA N/A
- Revenue Growth
- FMY N/A
- MAIA N/A
- 52 Week Low
- FMY $10.71
- MAIA $1.40
- 52 Week High
- FMY $12.17
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- FMY 50.15
- MAIA 47.29
- Support Level
- FMY $12.00
- MAIA $1.80
- Resistance Level
- FMY $12.11
- MAIA $2.18
- Average True Range (ATR)
- FMY 0.12
- MAIA 0.29
- MACD
- FMY 0.00
- MAIA -0.03
- Stochastic Oscillator
- FMY 47.25
- MAIA 4.85
About FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.